Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.

Inclusion Criteria:

• Clinical diagnosis of B Post hepatitic cirrhosis.
• Male or female patients between 18~65 years old.
• Written informed consent.

Exclusion Criteria:

• Child-Pugh C above 12, or ALT > 2×ULN, TBiL > 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.
• Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.
• Deformed man by the law.
• Pregnancy or breast feeding women, or unwilling to have contraception.
• Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.
• Enter other trials lately one month.
• Other cause of cirrhosis.